These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 29878661)

  • 1. Emerging therapies for haemophilia - Global perspective.
    Mahlangu J; Cerquiera M; Srivastava A
    Haemophilia; 2018 May; 24 Suppl 6():15-21. PubMed ID: 29878661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. General haemostatic agents--fact or fiction?
    Hedner U
    Pathophysiol Haemost Thromb; 2002; 32 Suppl 1():33-6. PubMed ID: 12214145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel products for haemostasis - current status.
    Oldenburg J; Albert T
    Haemophilia; 2014 May; 20 Suppl 4():23-8. PubMed ID: 24762271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia.
    Björkman S; Berntorp E
    Clin Pharmacokinet; 2001; 40(11):815-32. PubMed ID: 11735604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Haemophilia patients' unmet needs and their expectations of the new extended half-life factor concentrates.
    von Mackensen S; Kalnins W; Krucker J; Weiss J; Miesbach W; Albisetti M; Pabinger I; Oldenburg J
    Haemophilia; 2017 Jul; 23(4):566-574. PubMed ID: 28370896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel products for haemostasis.
    Shima M; Hermans C; de Moerloose P
    Haemophilia; 2014 May; 20 Suppl 4():29-35. PubMed ID: 24762272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The current and future role of plasma-derived clotting factor concentrate in the treatment of haemophilia A.
    Kevane B; O'Connell N
    Transfus Apher Sci; 2018 Aug; 57(4):502-506. PubMed ID: 30107983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Haemophilia gene therapy: From trailblazer to gamechanger.
    Evens H; Chuah MK; VandenDriessche T
    Haemophilia; 2018 May; 24 Suppl 6():50-59. PubMed ID: 29878653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Obesity in haemophilia patients: effect on bleeding frequency, clotting factor concentrate usage, and haemostatic and fibrinolytic parameters.
    Tuinenburg A; Biere-Rafi S; Peters M; Verhamme P; Peerlinck K; Kruip MJ; Laros-Van Gorkom BA; Roest M; Meijers JC; Kamphuisen PW; Schutgens RE
    Haemophilia; 2013 Sep; 19(5):744-52. PubMed ID: 23659471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Invasive procedures in patients with haemophilia: Review of low-dose protocols and experience with extended half-life FVIII and FIX concentrates and non-replacement therapies.
    Hermans C; Apte S; Santagostino E
    Haemophilia; 2021 Feb; 27 Suppl 3():46-52. PubMed ID: 32469134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined administration of FVIII and rFVIIa improves haemostasis in haemophilia A patients with high-responding inhibitors--a thrombin generation-guided pilot study.
    Livnat T; Martinowitz U; Azar-Avivi S; Zivelin A; Brutman-Barazani T; Lubetsky A; Kenet G
    Haemophilia; 2013 Sep; 19(5):782-9. PubMed ID: 23659442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioengineered molecules for the management of haemophilia: Promise and remaining challenges.
    Pipe SW
    Haemophilia; 2018 May; 24 Suppl 6():68-75. PubMed ID: 29878662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Haemophilia gene therapy: Progress and challenges.
    Lheriteau E; Davidoff AM; Nathwani AC
    Blood Rev; 2015 Sep; 29(5):321-8. PubMed ID: 26049173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New products for the treatment of haemophilia.
    Laffan M
    Br J Haematol; 2016 Jan; 172(1):23-31. PubMed ID: 26456702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapeutic innovations for hemophilia].
    Hermans C; Lambert C
    Rev Med Suisse; 2020 Jan; 16(676-7):47-52. PubMed ID: 31961083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy assessment of a new clotting factor concentrate in haemophilia A patients, including prophylactic treatment.
    Den Uijl I; Mauser-Bunschoten EP; Roosendaal G; Schutgens R; Fischer K
    Haemophilia; 2009 Nov; 15(6):1215-8. PubMed ID: 19686467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of pegylated full-length recombinant factor VIII with extended half-life for perioperative haemostasis in haemophilia A patients.
    Brand B; Gruppo R; Wynn TT; Griskevicius L; Lopez Fernandez MF; Chapman M; Dvorak T; Pavlova BG; Abbuehl BE
    Haemophilia; 2016 Jul; 22(4):e251-8. PubMed ID: 27328112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New assays for monitoring haemophilia treatment.
    Shima M; Matsumoto T; Ogiwara K
    Haemophilia; 2008 Jul; 14 Suppl 3():83-92. PubMed ID: 18510527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The promise and challenges of bioengineered recombinant clotting factors.
    Pipe SW
    J Thromb Haemost; 2005 Aug; 3(8):1692-701. PubMed ID: 16102035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of human plasma-derived clotting factor products and their role in haemostasis in patients with haemophilia: meeting report.
    Tarantino M; Ma A; Aledort L
    Haemophilia; 2007 Sep; 13(5):663-9. PubMed ID: 17880460
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.